Literature DB >> 20144388

An overview of glycemic control in the coronary care unit with recommendations for clinical management.

Mikhail Kosiborod1, Prakash Deedwania.   

Abstract

The observation that elevated glucose occurs frequently in the setting of acute myocardial infarction was made decades ago. Since then numerous studies have documented that hyperglycemia is a powerful risk factor for increased mortality and in-hospital complications in patients with acute coronary syndromes. While some questions in this field have been answered in prior investigations, many critical gaps in knowledge continue to exist and remain subjects of intense debate. This review summarizes what is known about the relationship between hyperglycemia, glucose control, and outcomes in critically ill patients with acute coronary syndromes, addresses the gaps in knowledge and controversies, and offers general recommendations regarding glucose management in the coronary care unit.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20144388      PMCID: PMC2787034          DOI: 10.1177/193229680900300614

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  83 in total

1.  Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery.

Authors:  H Kawano; T Motoyama; O Hirashima; N Hirai; Y Miyao; T Sakamoto; K Kugiyama; H Ogawa; H Yasue
Journal:  J Am Coll Cardiol       Date:  1999-07       Impact factor: 24.094

2.  Hyperglycemia may determine fibrinopeptide A plasma level increase in humans.

Authors:  A Ceriello; D Giugliano; A Quatraro; P Dello Russo; E Marchi; R Torella
Journal:  Metabolism       Date:  1989-12       Impact factor: 8.694

3.  Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study.

Authors:  Abhinav Goyal; Kenneth W Mahaffey; Jyotsna Garg; Jose C Nicolau; Judith S Hochman; W Douglas Weaver; Pierre Theroux; Gustavo B F Oliveira; Thomas G Todaro; Christopher F Mojcik; Paul W Armstrong; Christopher B Granger
Journal:  Eur Heart J       Date:  2006-04-12       Impact factor: 29.983

4.  Glucose, insulin and potassium applied as perioperative hyperinsulinaemic normoglycaemic clamp: effects on inflammatory response during coronary artery surgery.

Authors:  L Visser; C J Zuurbier; F J Hoek; B C Opmeer; E de Jonge; B A J M de Mol; H B van Wezel
Journal:  Br J Anaesth       Date:  2005-08-12       Impact factor: 9.166

5.  Blood glucose may condition factor VII levels in diabetic and normal subjects.

Authors:  A Ceriello; D Giugliano; A Quatraro; P Dello Russo; R Torella
Journal:  Diabetologia       Date:  1988-12       Impact factor: 10.122

6.  Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting.

Authors:  Anthony P Furnary; Guangqiang Gao; Gary L Grunkemeier; YingXing Wu; Kathryn J Zerr; Stephen O Bookin; H Storm Floten; Albert Starr
Journal:  J Thorac Cardiovasc Surg       Date:  2003-05       Impact factor: 5.209

7.  Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit.

Authors:  Philip A Goldberg; Mark D Siegel; Robert S Sherwin; Joshua I Halickman; Michelle Lee; Valerie A Bailey; Sandy L Lee; James D Dziura; Silvio E Inzucchi
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

8.  Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction.

Authors:  Rafael Díaz; Abhinav Goyal; Shamir R Mehta; Rizwan Afzal; Denis Xavier; Prem Pais; Susan Chrolavicius; Jun Zhu; Khawar Kazmi; Lisheng Liu; Andrzej Budaj; Mohammad Zubaid; Alvaro Avezum; Mikhail Ruda; Salim Yusuf
Journal:  JAMA       Date:  2007-11-28       Impact factor: 56.272

9.  Impact of fasting glycemia on short-term prognosis after acute myocardial infarction.

Authors:  Bruno Vergès; Marianne Zeller; Gilles Dentan; Jean-Claude Beer; Yves Laurent; Luc Janin-Manificat; Hamid Makki; Jean Eric Wolf; Yves Cottin
Journal:  J Clin Endocrinol Metab       Date:  2007-04-10       Impact factor: 5.958

10.  Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus.

Authors:  Paolo Gresele; Giuseppe Guglielmini; Massimiliano De Angelis; Silvia Ciferri; Marco Ciofetta; Emanuela Falcinelli; Carlo Lalli; Giovanni Ciabattoni; Giovanni Davì; Geremia B Bolli
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

View more
  5 in total

1.  Elective percutaneous coronary intervention: the relationship between preprocedural blood glucose levels and periprocedural myocardial injury.

Authors:  Mohsen Madani; Keivan Alizadeh; Sepideh Parchami Ghazaee; Abbas Zavarehee; Seifollah Abdi; Farshad Shakerian; Negar Salehi; Ata Firouzi
Journal:  Tex Heart Inst J       Date:  2013

2.  Blood glucose control for patients with acute coronary syndromes in Qatar.

Authors:  Kyle John Wilby; Eman Elmekaty; Ibtihal Abdallah; Masa Habra; Khalid Al-Siyabi
Journal:  Saudi Pharm J       Date:  2015-03-19       Impact factor: 4.330

3.  Selective protein kinase C inhibition switches time-dependent glucose cardiotoxicity to cardioprotection.

Authors:  Sean Brennan; Simona Esposito; Muhammad I M Abdelaziz; Christopher A Martin; Samir Makwana; Mark W Sims; Iain B Squire; Parveen Sharma; Amy E Chadwick; Richard D Rainbow
Journal:  Front Cardiovasc Med       Date:  2022-09-07

4.  Admission hyperglycemia and acute myocardial infarction: outcomes and potential therapies for diabetics and nondiabetics.

Authors:  Anjan K Chakrabarti; Priyamvada Singh; Lakshmi Gopalakrishnan; Varun Kumar; Meagan Elizabeth Doherty; Cassandra Abueg; Weici Wang; C Michael Gibson
Journal:  Cardiol Res Pract       Date:  2012-07-09       Impact factor: 1.866

5.  Effect of Acarbose on Long-Term Prognosis in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose Tolerance.

Authors:  Peng Yun; Ai-ming Du; Xue-jun Chen; Jing-cheng Liu; Hu Xiao
Journal:  J Diabetes Res       Date:  2015-12-06       Impact factor: 4.011

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.